Back to Search
Start Over
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
- Source :
- The Lancet Gastroenterology & Hepatology; October 2019, Vol. 4 Issue: 10 p781-793, 13p
- Publication Year :
- 2019
-
Abstract
- Norursodeoxycholic acid is an orally administered side chain-shortened homologue of ursodeoxycholic acid that undergoes hepatic enrichment with hepatoprotective, anti-inflammatory, and antifibrotic activity. We assessed the efficacy of two doses of norursodeoxycholic acid versus placebo for the treatment of non-alcoholic fatty liver disease.
Details
- Language :
- English
- ISSN :
- 24681253
- Volume :
- 4
- Issue :
- 10
- Database :
- Supplemental Index
- Journal :
- The Lancet Gastroenterology & Hepatology
- Publication Type :
- Periodical
- Accession number :
- ejs50656612
- Full Text :
- https://doi.org/10.1016/S2468-1253(19)30184-0